Why the study?
Current systemic antithrombotic therapies supporting extracorporeal membrane oxygenation are limited and hampered by thrombotic and hemorrhagic complications, necessitating an alternative approach.
Does EP-7041 prevent thrombosis without increasing bleeding compared to unfractionated heparin in ECMO models?
Does EP-7041 prevent thrombosis without increasing bleeding compared to unfractionated heparin in ECMO models?
EP-7041, a novel factor XIa inhibitor, demonstrates preclinical efficacy in preventing ECMO circuit thrombosis with a significantly lower bleeding risk compared to unfractionated heparin.
Supports testing EP-7041 in human ECMO; hypothesis-generating and requires clinical validation before adoption.
OBJECTIVES: Current approaches to systemic antithrombotic therapy in support of extracorporeal membrane oxygenation are limited and are hampered by both thrombotic and hemorrhagic complications. An alternative approach is needed. DESIGN: Inhibition of coagulation factor XI/activated factor XI is an appealing pathway for antithrombotic support of extracorporeal membrane oxygenation. Selective inhibition of the contact pathway of coagulation could reduce bleeding risk, and because factor XI is linked with the inflammatory and complement systems, it can also be viewed as a biologically plausible target for the prevention of abnormal thrombosis during extracorporeal membrane oxygenation. CONCLUSIONS: We introduce initial information on EP-7041, a parenteral, potent, and selective, small-molecule activated factor XIa inhibitor with pharmacodynamic and pharmacokinetic characteristics that appear well suited for use in a critical care environment.
No takes yet. Share an insight, caveat, or question.
Pollack et al. (2020) studied Extracorporeal membrane oxygenation (ECMO). EP-7041 vs. Unfractionated heparin (UFH) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: